Eisai Clinical Trials
Study Overview
E7389
eribulin mesilate
NCT03245450, 2016-003352-67, SNCTP000004098
Mar 2018 - May 2021
Refractory or Recurrent Solid Tumors
1. Phase 1: Recommended Phase 2 Dose (RP2D) of Eribulin Mesilate in Combination With Irinotecan Hydrochloride [Time Frame: First dose of study drug up to Cycle 1 (Cycle length=21 days)]
2. Phase 2: Objective Response Rate (ORR) [Time Frame: From date of first dose of study drug until disease progression, development of unacceptable toxicity, withdrawal of consent, or up to approximately 2 years 4 months]
2. Phase 2: Objective Response Rate (ORR) [Time Frame: From date of first dose of study drug until disease progression, development of unacceptable toxicity, withdrawal of consent, or up to approximately 2 years 4 months]
-
Males and females 6 Months to 25 Years (Child, Adult)
-
Completed -
Phase 1 / 2
France, Germany, Greece, Italy, Poland, Spain, Switzerland, United Kingdom See moreData Sharing
ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.
CSDR Sharing is not available for this study.
CSDR Availability Clinical Trial Data Redacted documents may be available upon request for this study.
Document type Availability Protocol SAP Sample CRF Full CSR